All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Camila Morrone in ...

In my Boston Globe review of Louise Erdrich’s 2016 novel “LaRose,” I described her as “an artist of the liminal.” “Python’s Kiss,” Erdrich’s new collection of stories written over 20 years, testifies ...

The University of Houston System's general counsel defended the dual course reviews underway across UH campuses on Thursday, telling the Board of Regents that top administrators chose an approach that ...

Bottom Line: Why Choose UWorld? After spending time inside the platform, UWorld feels the most dialed in for serious ACT repetition and mistake analysis. It keeps everything centered on practice ...

The 2026 Mazda CX-50 reminds me of T.S. Eliot’s poem “Burnt Norton”: “What might have been and what has been/Point to one end, which is always present.” Because I’m classy. Introduced for model-year ...

The Dell XPS 14 brings the company’s flagship laptop back into competition with speedy Intel Core Series 3 chips and a redesign that’s more practical, yet still premium. In 2022, Dell took a big swing ...

The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...

Beckoning audiences on a whimsical jaunt to always look on the bright side of life, the touring revival of “Spamalot” is especially winning for its unabashed determination to deliver on all manners of ...

The Food and Drug Administration reversed course and agreed to begin a review of Moderna’s MRNA1.16%increase; green up pointing triangle application to sell a new seasonal flu shot after the vaccine ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...